SHOC2 and neoplasm: As seen with SHOC2, intrapathway dual inhibition (vertical inhibition) at the level of RAF or ERK (MEKi plus RAFi or MEKi plus ERKi) also impairs feedback reactivation, leads to more potent and sustained ERK suppression, promotes tumour regression in preclinical models in RAS-mutant cells49,61,67.